News

Public · Published

Signatera™ Genome with Phased and Structural Variants Highlighted in ESMO Presidential Symposium, Supporting the Critical Role of MRD-Guided Treatment in Bladder Cancer

Natera presented results from the phase III VOLGA trial in muscle-invasive bladder cancer. The data showed that patients who stayed Signatera-negative had a 24-month event-free survival rate of 91%, compared with 81% for those who cleared ctDNA before surgery and 55% for those who remained positive.

Published:

Updated:

What happened

Natera presented results from the phase III VOLGA trial in muscle-invasive bladder cancer. The data showed that patients who stayed Signatera-negative had a 24-month event-free survival rate of 91%, compared with 81% for those who cleared ctDNA before surgery and 55% for those who remained positive.

Confirmed

Global impact / market context

For Natera investors, this supports the clinical value of its Signatera test in guiding treatment for bladder cancer. Stronger evidence can lead to more doctors ordering the test, which may increase the company's revenue and strengthen its position in the growing market for MRD testing, which means measuring tiny amounts of cancer DNA left after treatment.

Analyst inference

The data were featured in a Presidential Symposium at ESMO Congress 2026, a high-profile medical meeting that can raise awareness among oncologists. If adopted into treatment guidelines, Signatera could become a standard tool for bladder cancer, potentially expanding its use and supporting Natera's sales growth.

Analyst inference

What to watch

  1. The VOLGA trial results showed that Signatera ctDNA dynamics were highly predictive of event-free survival, with a 24-month rate of 91% for persistently negative patients versus 55% for those who remained positive. Confirmed
  2. Natera may seek to expand the use of Signatera Genome with Phased and Structural Variants into other cancer types, which could increase the test's addressable market but will require further clinical trials and regulatory clearances. Proposed
  3. Investors should watch for updates on reimbursement decisions and guideline inclusion, because favorable coverage would likely drive test adoption and revenue growth for Natera's MRD franchise. Analyst inference

Evidence

  • Original source link unavailable